LLY - Dyne: H2 2024 Muscle Disease Data Could Boost Value

2024-03-05 14:48:29 ET

Summary

• Dyne Therapeutics, Inc. results from the phase 1/2 ACHIEVE study, using DYNE-101 for the treatment of patients with Myotonic Dystrophy Type 1, expected in H2 2024.
• The Myotonic Dystrophy Type 1 treatment market is expected to reach $2.78 billion by 2033.
• Results from the phase 1/2 DELIVER study, using DYNE-251, for the treatment of patients with Duchenne Muscular Dystrophy, expected in H2 2024.
• The global Duchenne Muscular Dystrophy treatment market is expected to reach $4.32 billion by 2029.

Dyne Therapeutics, Inc. ( DYN ) is advancing the use of its FORCE platform to target skeletal muscle disorders. This would be with the use of modern oligonucleotide technology drugs like DYNE-101 and DYNE-251, which are both being advanced for the treatment of patients with myotonic dystrophy type 1 [DM1] and Duchenne Muscular Dystrophy [DMD] with specific exon skipping mutations. The DYNE-101 candidate is being advanced for the treatment of patients with DM1 in the ongoing phase 1/2 ACHIEVE trial and then DYNE-251 is being tested in the ongoing phase 1/2 DELIVER trial. The significance of looking into this biotech is that it is expected to present preliminary results from both of these studies on March 6th of 2024 at the Muscular Dystrophy Association [MDA] Clinical and Scientific Conference....

For further details see: